Mounjaro KWIKPEN 15mg (Tirzepatide Injection) 15MG/0.6 ML(2.4 ML)

Mounjaro KWIKPEN 15mg is a GIP/GLP-1 receptor agonist used in the management of type 2 diabetes mellitus and for weight management.

• Type 2 diabetes mellitus: Helps control blood sugar levels in adults with type 2 diabetes.
• Obesity: Aids in weight loss and weight management in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with weight-related complications such as high blood pressure, type 2 diabetes, or dyslipidemia.
• Weight-related complications: Assists in managing conditions like high blood pressure, high cholesterol, and sleep apnea associated with obesity.

• Tirzepatide, the active ingredient in Mounjaro KWIKPEN 15mg, is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes weight loss by acting on these receptors in the pancreas and brain.

Mounjaro KWIKPEN 15mg may cause various side effects, ranging from common to serious.

Common Side Effects

• Nausea: Feeling sick to the stomach.
• Vomiting: Expelling stomach contents through the mouth.
• Diarrhea: Frequent, loose, or watery bowel movements.
• Constipation: Difficulty in passing stools.
• Injection site reactions: Redness, swelling, or itching at the injection site.
• Fatigue: Feeling unusually tired or weak.
• Decreased appetite: Reduced desire to eat.
• Abdominal pain: Discomfort or pain in the stomach area.

Serious or Rare Side Effects

• Pancreatitis: Inflammation of the pancreas, which can cause severe abdominal pain.
• Hypoglycemia: Low blood sugar levels, which can cause dizziness, confusion, or fainting.
• Kidney problems: Changes in kidney function, which may require monitoring.
• Allergic reactions: Severe allergic reactions, including rash, itching, swelling, severe dizziness, or trouble breathing.
• Gallbladder problems: Including gallstones or inflammation of the gallbladder.
• Increased risk of thyroid tumors: In animal studies, tirzepatide has been linked to an increased risk of thyroid C-cell tumors.
• Vision changes: Blurred vision or other changes in vision.

Mounjaro KWIKPEN 15mg should be used with caution and under medical supervision.

• Administration: Administer subcutaneously once a week, preferably on the same day each week.
• Monitoring: Regularly monitor blood sugar levels and adjust the dosage as needed.
• Hypoglycemia: Be aware of the signs of low blood sugar and have a source of glucose available.
• Pancreatitis: Discontinue use and seek medical attention if severe abdominal pain occurs.
• Kidney function: Monitor kidney function regularly, especially in patients with a history of kidney problems.
• Allergic reactions: Seek immediate medical attention if signs of an allergic reaction occur.
• Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Mounjaro KWIKPEN 15mg may interact with other medications, potentially affecting its efficacy or increasing the risk of side effects.

Major Interactions (Avoid)

• Insulin: Concomitant use may increase the risk of hypoglycemia.
• Sulfonylureas: May also increase the risk of hypoglycemia.
• Other GLP-1 receptor agonists: May enhance the risk of gastrointestinal side effects.

Moderate Interactions (Monitor Closely)

• Oral medications: May affect the absorption of oral medications due to slowed gastric emptying.
• Diuretics: May affect blood pressure and electrolyte balance.
• Corticosteroids: May increase the risk of hyperglycemia.
• Beta-blockers: May mask the symptoms of hypoglycemia.
• Thyroid medications: May require dose adjustments due to changes in metabolism.